About: A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis
Creator	Xiong, Sidong Yue, Yan Wu, Fei Dong, Chunsheng Fan, Xingjuan
Source	Elsevier; Medline; PMC
abstract	Abstract Recombinant vesicular stomatitis virus (VSV) is widely used as a vaccine platform. However, the capacity of VSV-based vaccines to induce mucosal immunity has not been fully investigated. In the present study, a recombinant VSV expressing coxsackievirus B3 (CVB3) major immunogen VP1 has been generated and the immune protection elicited by VSV-VP1 was evaluated. We demonstrated that intranasal delivery of VSV-VP1 can induce a potent antigen-specific mucosal immune response as well as a systemic immune response, particularly the induction of polyfunctional T cells. Importantly, mice immunized with VSV-VP1 were better protected against CVB3-induced viral myocarditis than those receiving a chitosan-formulated DNA vaccine. Increased dendritic cell (DC) maturation in the mesenteric lymph node (MLN) was observed in the mice vaccinated with VSV-VP1, which could be a potential mechanism for the protective immune response. These findings support VSV as a viral delivery vector that can induce robust mucosal immunity that should be considered for further vaccine development.
has issue date	2014-06-30(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2014.05.052
bibo:pmid	24874923
has license	els-covid
sha1sum (hex)	47657978dd272aff0e0be8c8aa3877b8db673067
schema:url	https://doi.org/10.1016/j.vaccine.2014.05.052
resource representing a document's title	A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis
has PubMed Central identifier	PMC7115516
has PubMed identifier	24874923
schema:publication	Vaccine
resource representing a document's body	covid:47657978dd272aff0e0be8c8aa3877b8db673067#body_text
is schema:about of	named entity 'DNA vaccine' named entity 'T cells' named entity 'coxsackievirus' named entity 'induced' named entity 'VIRAL MYOCARDITIS' named entity 'DENDRITIC CELL MATURATION' named entity 'MUCOSAL IMMUNE RESPONSE' named entity 'CAPACITY' named entity 'FULLY' named entity 'INCREASED' named entity 'ELICITED BY' named entity 'INDUCED' named entity 'FINDINGS' named entity 'RECOMBINANT' named entity 'MAJOR' named entity 'PLATFORM' named entity 'EVALUATED' named entity 'RECEIVING' named entity 'VIRAL MYOCARDITIS' named entity 'SYSTEMIC' named entity 'VP1' named entity 'VESICULAR STOMATITIS VIRUS' named entity 'IMMUNE RESPONSE' named entity 'MESENTERIC LYMPH NODE' named entity 'CHITOSAN' named entity 'BETTER' named entity 'COXSACKIEVIRUS B3' named entity 'BASED' named entity 'VACCINE DEVELOPMENT' named entity 'COXSACKIEVIRUS B3' named entity 'COULD BE' named entity 'CONSIDERED' named entity 'IMMUNE RESPONSE' named entity 'POTENTIAL' named entity 'MUCOSAL IMMUNITY' named entity 'ANTIGEN' named entity 'PRESENT' named entity 'VECTOR' named entity 'BASED' named entity 'OBSERVED' named entity 'DEMONSTRATED' named entity 'THESE' named entity 'ELICITS' named entity 'VACCINES' named entity 'INDUCE' named entity 'MECHANISM' named entity 'DELIVERY' named entity 'INVESTIGATED' named entity 'IMMUNE PROTECTION' named entity 'SPECIFIC' named entity 'INTRANASAL' named entity 'VACCINE' named entity 'VESICULAR STOMATITIS VIRUS' named entity 'INDUCTION' named entity 'USED' named entity 'IMMUNOGEN' named entity 'MATURATION' named entity 'MICE' named entity 'IMMUNIZED' named entity 'ROBUST' named entity 'STUDY' named entity 'VIRAL' named entity 'MUCOSAL VACCINE' named entity 'INDUCED' named entity 'DENDRITIC CELL' named entity 'T CELLS' named entity 'SUPPORT' named entity 'VACCINATED' named entity 'GENERATED' named entity 'DNA VACCINE' covid:arg/47657978dd272aff0e0be8c8aa3877b8db673067 named entity 'MLN' named entity 'immunogen' named entity 'vesicular stomatitis virus' named entity 'robust' named entity 'platform' named entity 'immune response'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software